Drug Profile
AZD 8683
Alternative Names: AZD8683Latest Information Update: 04 Feb 2013
Price :
$50
*
At a glance
- Originator AstraZeneca; Pulmagen Therapeutics
- Developer AstraZeneca
- Class
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 31 Dec 2012 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 31 Dec 2012 Discontinued - Phase-I for Chronic obstructive pulmonary disease in USA (Inhalation)
- 31 Dec 2012 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Poland (Inhalation)